Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2022 revenue of $11.7 million, a 15% increase from Q2 2021. Excluding COVID-19 revenues, constant currency growth was 36%. Gross margin improved to 65%, with a record adjusted gross margin of 67%. However, operating loss widened to $24.1 million, up from $15.9 million year-over-year. The company maintained its revenue growth guidance for FY 2022 at 30% to 35%, though overall revenue is now expected between $47 million and $49.5 million due to currency fluctuations.

SOPHiA GENETICS (Nasdaq: SOPH) has announced its inaugural Investor Day scheduled for September 20, 2022, at PUBLIC Hotel in New York City. The event will commence at 1:30 p.m. EDT and conclude by approximately 5:30 p.m. EDT. Presentations will be made by CEO Dr. Jurgi Camblong and the executive leadership team, followed by a Q&A session and reception. Due to limited capacity, registration is required. The event will also be available via live webcast, with replays accessible the next day.

SOPHiA GENETICS (Nasdaq: SOPH) announced that CFO Ross Muken will participate as a panelist at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, in Boston, MA. Muken will join other industry leaders for the panel titled “Leveraging Omics-Based Data and Analytics to Advance Precision Health to the Next Level”, starting at 9:30 a.m. EST. A live webcast and replay will be available on the company's investor relations website.

More than 790 institutions globally utilize the SOPHiA DDM™ Platform, which analyzes complex multimodal data for healthcare advancements.

SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q2 2022 on August 9, 2022, before U.S. markets open. The company will host a conference call at 8:30 a.m. EDT to discuss these results and the business outlook. The conference call will be available for live streaming on their Investor Relations website, with a replay to follow. SOPHiA GENETICS is focused on data-driven medicine and serves over 790 institutions globally with its SOPHiA DDM™ Platform, which analyzes multimodal data for healthcare and research purposes.

SOPHiA GENETICS held its Annual General Meeting on June 15, 2022, in St-Sulpice, Switzerland. Shareholders approved all agenda items, with detailed voting results available on the Company's website and to be filed with the SEC. Jean-Michel Cosséry was welcomed as a new board member, bringing over 25 years of industry experience. SOPHiA GENETICS aims to standardize data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 790 institutions worldwide.

SOPHiA GENETICS (Nasdaq: SOPH) has published its inaugural Environmental, Social and Governance (ESG) Impact Summary. This document outlines the Company's policies and initiatives related to innovation, patient data protection, and employee empowerment. According to Co-Founder and CEO Dr. Jurgi Camblong, the report marks the initial steps in their ESG journey, reflecting their commitment to patient care and sustainable healthcare. The ESG Impact Summary is accessible via their website and aims to enhance transparency about the Company’s practices in these vital areas.

SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with IDIBAPS and Diagnóstica Longwood to enhance Chronic Lymphocytic Leukemia (CLL) care at the European Hematology Association Congress. This partnership aims to consolidate various guideline recommendations into a single application, improving CLL characterization and research practices in Iberia. Leveraging the SOPHiA DDM™ Platform, hematopathologists can access essential guidelines and identify CLL-specific genes, potentially enhancing patient care for the 100,000+ global annual CLL cases.

SOPHiA GENETICS provided an update on its DEEP-Lung-IV clinical study during the 2022 ASCO Annual Meeting. The study focuses on predicting patient response to immunotherapy using multimodal data analysis. Currently, 19 sites across 7 countries have recruited over 500 patients. Early findings suggest promising potential for identifying predictive signatures for individual patients. Additionally, an agreement with GE Healthcare aims to enhance radiomics analysis workflows. Insights from this study could significantly impact precision medicine for stage IV non-small cell lung cancer.

SOPHiA GENETICS (Nasdaq: SOPH) reported Q1 2022 revenue of $10.9 million, marking a year-over-year growth of 21%. Excluding COVID-19 revenues, the constant currency growth reached 35%. The company maintains its 2022 revenue growth guidance of 30% to 35%, despite a stronger U.S. dollar impacting reported figures. The total genomic profiles analyzed surpassed 1,000,000, and total recurring customers increased to 384. However, the operating loss rose to $25 million, up from $14.1 million in Q1 2021, with a net loss of $25.5 million or $0.40 per share.